Nature Communications (Jun 2022)
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
- Joyce V. Lee,
- Filomena Housley,
- Christina Yau,
- Rachel Nakagawa,
- Juliane Winkler,
- Johanna M. Anttila,
- Pauliina M. Munne,
- Mariel Savelius,
- Kathleen E. Houlahan,
- Daniel Van de Mark,
- Golzar Hemmati,
- Grace A. Hernandez,
- Yibing Zhang,
- Susan Samson,
- Carole Baas,
- Laura J. Esserman,
- Laura J. van ‘t Veer,
- Hope S. Rugo,
- Christina Curtis,
- Juha Klefström,
- Mehrdad Matloubian,
- Andrei Goga
Affiliations
- Joyce V. Lee
- Department of Cell and Tissue Biology, University of California
- Filomena Housley
- Department of Cell and Tissue Biology, University of California
- Christina Yau
- Cancer and Developmental Therapeutics Program, Buck Institute for Research on Aging
- Rachel Nakagawa
- Department of Cell and Tissue Biology, University of California
- Juliane Winkler
- Department of Cell and Tissue Biology, University of California
- Johanna M. Anttila
- Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki
- Pauliina M. Munne
- Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki
- Mariel Savelius
- Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki
- Kathleen E. Houlahan
- Stanford Cancer Institute, Stanford University School of Medicine
- Daniel Van de Mark
- Department of Cell and Tissue Biology, University of California
- Golzar Hemmati
- Department of Cell and Tissue Biology, University of California
- Grace A. Hernandez
- Department of Cell and Tissue Biology, University of California
- Yibing Zhang
- Department of Cell and Tissue Biology, University of California
- Susan Samson
- Helen Diller Family Comprehensive Cancer Center, University of California
- Carole Baas
- Alamo Breast Cancer Foundation
- Laura J. Esserman
- Helen Diller Family Comprehensive Cancer Center, University of California
- Laura J. van ‘t Veer
- Helen Diller Family Comprehensive Cancer Center, University of California
- Hope S. Rugo
- Helen Diller Family Comprehensive Cancer Center, University of California
- Christina Curtis
- Stanford Cancer Institute, Stanford University School of Medicine
- Juha Klefström
- Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki
- Mehrdad Matloubian
- Department of Medicine, Division of Rheumatology and Rosalind Russell/Ephraim P Engleman Rheumatology Research Center, University of California
- Andrei Goga
- Department of Cell and Tissue Biology, University of California
- DOI
- https://doi.org/10.1038/s41467-022-31238-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
The oncoprotein c-Myc is often overexpressed in triple negative breast cancer and has a role in tumor progression and resistance to therapy. Here the authors show that elevated MYC expression is correlated with low immune infiltration, diminished MHC-I pathway expression and that CpG/aOX40 treatment could overcome resistance to PD-L1 blockade in MYC-high breast tumors.
